DERM.US Journey Medical Corp

Healthcare Biotechnology USA Stocks
5.50 USD
Close of Nov 14, 2026
4.00 9.56
Market cap
USD 122M
P/E
-
P/B
3.79x
ROE
-15.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DERM.US undervalued?

Graham number

The Graham number of Journey Medical Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Journey Medical Corp fundamental analysis

No fundamental analysis for Journey Medical Corp yet.

Journey Medical Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Journey Medical Corp

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline …

Full company profile